According to MSNBC, this past Tuesday, Federal health regulators said they were going to add new labels regarding the risks of infection to organ transplant drugs made by several drugmakers. Some of those drugmakers include Roche and Novartis.
This move is a result of FDA receiving reports of dangerous viral infections in patients who took these drugs, “which are typically used to avoid rejection following kidney transplant.”
The drugs that will have these new labels include: Roche’s CellCept, Novartis’ Myfortic, Wyeth’s Rapamune, Neoral, and Sandimmune.
FDA is continuing to monitor any reports of safety problems with these medications. FDA has also said that “physicians should carefully monitor patients for signs of viral infection, which can sometimes lead to kidney failure.”
Comments for this article are closed.